Please use this identifier to cite or link to this item:
Title: Targeted Therapy For RET-Rearranged Non-Small Cell Lung Cancer: Clinical Development And Future Directions
Authors: ACKERMANN, Christoph JakobSTOCK, GustavoTAY, RebeccaDAWOD, MohammedGOMES, FabioCALIFANO, Raffaele
Citation: ONCOTARGETS AND THERAPY, v.12, p.7857-7864, 2019
Abstract: Approximately 1-2% of unselected patients with Non-small Cell Lung Cancer (NSCLC) harbor RET rearrangements resulting in enhanced cell survival and proliferation. The initial treatment strategy for RET rearranged NSCLC has been multi-target tyrosine kinase inhibition. With overall response rates (ORR) of 16-53% and a median progression-free survival (PFS) of 4.5-7.3 months these outcomes are clearly inferior to the efficacy outcomes of selective tyrosine kinase inhibitors (TKI) in other oncogene-addicted NSCLC. Additionally, multi-kinase inhibition in RET-driven NSCLC patients showed concerning rates of high-grade toxicity, mainly induced by anti-VEGFR-kinase activity. Novel selective RET inhibitors like BLU-667, LOXO-292 and RXDX-105 have been recently investigated in early phase clinical trials showing promising efficacy with a manageable toxicity profile.
Appears in Collections:

Artigos e Materiais de Revistas Científicas - HC/ICESP
Instituto do Câncer do Estado de São Paulo - HC/ICESP

Files in This Item:
File Description SizeFormat 
art_ACKERMANN_Targeted_Therapy_For_RETRearranged_NonSmall_Cell_Lung_Cancer_2019.PDFpublishedVersion (English)353.74 kBAdobe PDFThumbnail

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.